Evaluation of Semaphorin 3G (SEMA3G) as a biofluid biomarker of cerebral amyloid angiopathy: evidence from neurodegenerative disease and memory clinic cohorts

Introduction: Cerebral amyloid angiopathy (CAA) is characterised by amyloid-beta (Aβ) deposition in cerebral vessels, and frequently co-occurs with Alzheimer's disease (AD). Diagnosis based on MRI-based Boston criteria is not definitive, and CAA biofluid biomarkers are needed. Semaphorin 3G (SEMA3G) was recently shown to be selectively enriched in CAA-affected vessels, and correlated with CAA severity. We therefore evaluated SEMA3G as a biofluid biomarker of CAA. Methods: SEMA3G profiles were examined across diagnoses in the Global Neurodegeneration Proteomics Consortium dataset (GNPC) in cerebrospinal fluid (CSF) (N=1982) and plasma (N=6917). SEMA3G was then evaluated in the Healthy Brain Ageing (HBA) memory clinic cohort (N=161) with 3T MRI, where lobar cerebral microbleed burden was used as a proxy for CAA likelihood, with participants grouped by microbleed count (0, 1-2, or ≥3). Results: CSF and plasma SEMA3G were significantly lower in AD and frontotemporal dementia (FTD) compared to cognitively unimpaired controls in GNPC, and were associated with hypertension. Longitudinally, plasma SEMA3G declined significantly over time in mild cognitive impairment (MCI) and AD. In the HBA cohort, plasma SEMA3G did not differ by cerebral microbleed burden on MRI, nor correlate with plasma Aβ isoforms and white matter hyperintensities. Discussion : Although CSF and plasma SEMA3G levels were significantly lower in AD and FTD, plasma SEMA3G was not associated with CAA-associated MRI features in individuals at risk of AD. While these findings do not support plasma SEMA3G for identifying individuals with higher CAA-associated burden, its potential utility warrants further evaluation in genetically susceptible or neuropathologically confirmed CAA cohorts.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-20
DOI
https://doi.org/10.64898/2026.11.18.26368450
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Evaluation of Semaphorin 3G (SEMA3G) as a biofluid biomarker of cerebral amyloid angiopathy: evidence from neurodegenerative disease and memory clinic cohorts

Johannes C. Michaelian, Eleanor Drummond, Dongang Wang, Sharon Linda Naismith et al.
3 links
medRxiv
Intracerebral and Subarachnoid Hemorrhage Research
preprint

Evaluation of Semaphorin 3G (SEMA3G) as a biofluid biomarker of cerebral amyloid angiopathy: evidence from neurodegenerative disease and memory clinic cohorts

Johannes C. Michaelian, Eleanor Drummond, Dongang Wang, Sharon Linda Naismith, Lisa Shi, Michael Harry Barnett, Chenyu Wang
preprint en

Abstract

Introduction: Cerebral amyloid angiopathy (CAA) is characterised by amyloid-beta (Aβ) deposition in cerebral vessels, and frequently co-occurs with Alzheimer's disease (AD). Diagnosis based on MRI-based Boston criteria is not definitive, and CAA biofluid biomarkers are needed. Semaphorin 3G (SEMA3G) was recently shown to be selectively enriched in CAA-affected vessels, and correlated with CAA severity. We therefore evaluated SEMA3G as a biofluid biomarker of CAA. Methods: SEMA3G profiles were examined across diagnoses in the Global Neurodegeneration Proteomics Consortium dataset (GNPC) in cerebrospinal fluid (CSF) (N=1982) and plasma (N=6917). SEMA3G was then evaluated in the Healthy Brain Ageing (HBA) memory clinic cohort (N=161) with 3T MRI, where lobar cerebral microbleed burden was used as a proxy for CAA likelihood, with participants grouped by microbleed count (0, 1-2, or ≥3). Results: CSF and plasma SEMA3G were significantly lower in AD and frontotemporal dementia (FTD) compared to cognitively unimpaired controls in GNPC, and were associated with hypertension. Longitudinally, plasma SEMA3G declined significantly over time in mild cognitive impairment (MCI) and AD. In the HBA cohort, plasma SEMA3G did not differ by cerebral microbleed burden on MRI, nor correlate with plasma Aβ isoforms and white matter hyperintensities. Discussion : Although CSF and plasma SEMA3G levels were significantly lower in AD and FTD, plasma SEMA3G was not associated with CAA-associated MRI features in individuals at risk of AD. While these findings do not support plasma SEMA3G for identifying individuals with higher CAA-associated burden, its potential utility warrants further evaluation in genetically susceptible or neuropathologically confirmed CAA cohorts.

medRxiv
The University of Sydney (AU)
Good health and well-being
Intracerebral and Subarachnoid Hemorrhage Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon